NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE · Medical Devices · USD

Smith & Nephew plc (SNN) Stock Analysis

Smith & Nephew plc (SNN) is a Medical Devices stock listed on NYSE and quoted in US Dollar.

SNN

$28.87

+$0.18 (+0.63%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SNN with… →

SNN Key Statistics

As of Sep 4, 2026
Trading
Open
$28.77
Previous Close
$28.69
Day's Range
28.69–29.02
52-Week Range
28.48–38.79
Volume
851.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.68
Valuation
Market Cap
$12.08B
P/E Ratio
19.64
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
11.81
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.10
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.92
EPS (ttm)Profit attributable to each share over the last twelve months.
1.47
Financials (FY)
Revenue (FY)
$6.16B+6.09%
Net Income (FY)
$625.00M+51.70%
Profit marginThe share of revenue left as profit after all costs and taxes.
10.08%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
418.51M
1-Year Return
−21.49%
Dividend and dates
Dividend
$0.79+2.75%
Ex-Dividend Date
October 2, 2026
Avg Volume
1.63M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SNN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−10.67%
2025+36.81%
2024−7.34%
2023+4.44%
2022−20.20%
2021−16.21%
2020−10.40%
2019+30.84%
2018+8.90%
2017+18.57%
2016 (partial year)−9.40%

As of September 4, 2026.

SNN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$6.16B$625.00M10.1%
2024$5.81B$412.00M7.1%
2023$5.55B$263.00M4.7%
2022$5.22B$223.00M4.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$6.16B$4.19B$857.00M$625.00M10.1%
2024$5.81B$4.05B$860.00M$412.00M7.1%
2023$5.55B$3.82B$620.00M$263.00M4.7%
2022$5.22B$3.68B$634.00M$223.00M4.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SNN Dividend History

$0.76+1.6% vs 2024

Dividends per share, 2025 · 2 payments

YearDividends per sharePaymentsChange
2026*$0.481—
2025$0.762+1.6%
2024$0.752+0.0%
2023$0.752+0.0%
YearDividends per sharePaymentsChange
2026 (partial year)$0.481—
2025$0.762+1.6%
2024$0.752+0.0%
2023$0.752+0.0%
2022$0.752+0.0%
2021$0.752+0.0%
2020$0.752+3.0%
2019$0.732−0.8%
2018$0.732+19.2%
2017$0.622+150.4%
2016$0.251—

Most recent payment: $0.48 per share, ex-dividend March 27, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

SNN Valuation vs Medical Devices Median

Median of 151 stocks
MetricSNNMedical Devices medianvs median
P/E19.6426.8027% below
P/S ratio1.922.9836% below
Profit margin10.08%−1.69%11.8 pts above

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Smith & Nephew plc (SNN) is capitalised at $12.08B on the latest close. It is classified in the Medical Devices industry, within the Healthcare sector. Headcount on file is 17,000.

Over the past 52 weeks the price has ranged from $28.48 to $38.79. The most recent close on file for SNN is $28.87, dated September 4, 2026. That is +$0.18 (+0.63%) against the previous close. The latest close sits 1.37% above that 52-week low.

Financial Health

In fiscal 2025, Smith & Nephew plc reported revenue of $6.16B. Against the prior fiscal year total of $5.81B, that is a change of +6.09%. Net income for the same year was $625.00M. That is +51.70% against the prior fiscal year. The reported profit margin is 10.08%. That is 11.8 percentage points above the Medical Devices median of −1.69%. Earnings per share on a trailing basis come to 1.47.

Across the 4 fiscal years on file, revenue moves from $5.22B in 2022 to $6.16B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 19.64. That is 26.72% below the Medical Devices median of 26.8. On forward earnings the ratio is 11.81. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.1. The price-to-sales ratio is 1.92. On price-to-sales that is 35.56% below the Medical Devices median of 2.98. The medians here are taken across 151 Medical Devices companies that report the metric.

The trailing one-year price return is −21.49%. Across 10 years the annualized return works out at +0.81%. The reported beta is 0.68. Annualized volatility over the trailing 10 years is 27.03%.

Growth & Income

The trailing dividend yield is 2.75%. That is 1.4 percentage points above the Medical Devices median yield of 1.38%. The indicated annual rate is $0.79 a share. The ex-dividend date on file is October 2, 2026. Dividends are recorded for 11 calendar years; 2026 shows 1 payments totalling $0.48 a share. The year before, 2025, totalled $0.76 a share.

Across the complete calendar years on file, 2025 returned +36.81% and 2022 returned −20.20%. Of the 9 complete calendar years on file, 5 finished higher. So far in 2026 the price is −10.67%.

Peer Comparison

Smith & Nephew plc (SNN) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Smith & Nephew plc SNN $12.08B 19.6
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. Smith & Nephew plc trades at a P/E of 19.6.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Smith & Nephew plc

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Visit website →